

Supplemental Table 1 Patient demographics

No.	Age	BMI (kg/m²)	Diag.	Indic.	INTERMACS	NYHA	Months post- op	LVEF (%)	RV Dysfn	Baseline speed (rpm)	Medications
1	62	20	VDCM	BTT	2	2	3	20	Mod	2500	W, A, C, RAS, L
2	70	22	IDCM	BTT	2TCS	2	4	20	Nil	2600	W, A, S, PV
3	52	26	IschCM	BTT	2TCS	3	3	20	Mild	2600	W, A, C, RAS, S
4	60	23	IDCM	BTT	2TCS	2	4	40	Mild	2600	W, A, C, B, RAS, L, D
5	66	26	VDCM	BTT	2TCS	2	2	25	Mild- Mod	2600	W, A, C, D, L, B, RAS, S
6	41	30	MCM	BTT	2	2	10	25	Nil	2800	W, A, C, B, AM, RAS, L, PV
7	41	29	IschCM	BTT	1	3	5	20	Mild	2700	W, A, C, RAS, L
8	52	26	IschCM	BTT	1	2	16	40	Nil	2600	W, A, C, B, RAS, S

9	63	23	IschCM	DT	2	2	12	20	Nil	2600	W, A, C, L, S, N
10	54	25	ACM	BTT	1	3	3	20	Mod	2500	W, A, C, AM, RAS, L
11	63	22	IDCM	BTT	3	1	2	25	Nil	2800	W, A, C, AM, RAS, S
12	62	27	IschCM	BTT	2	2	3	25	Nil	2600	W, A, B, AM, RAS, L, S, N
13	71	25	IschCM	BTT	3	1	3	20	Mild	2600	W, A, B, RAS, S
14	56	29	IschCM	BTT	2	2	5	25	Nil	2600	W, A, B, AM, L, S
Mean (SD)	58.1 (9.3)	25.2 (3.0)				2.1 (0.6)	5.4 (4.2)	24.6 (6.9)		2621 (89.3)	

No., subject number; Diag., diagnosis; VDCM, viral dilated cardiomyopathy; IDCM, idiopathic dilated cardiomyopathy; IschCM, ischaemic cardiomyopathy; MCM, mitochondrial cardiomyopathy; ACM, Anthracycline-induced cardiomyopathy; CVD, cardiovascular disease; Indic., indication; BTT, bridge-to-transplant; DT, destination therapy; TCS, temporary circulatory support; LVEF, left ventricular ejection fraction; RV Dysfn, right ventricular dysfunction; Mod, moderate; TVR, tricuspid valve repair; W, warfarin; A, aspirin; C, clopidogrel; RAS, renin-angiotensin-aldosterone antagonists; L, loop diuretic; S, statin; PV, pulmonary vasodilator; B, beta-blocker; D, Digoxin; AM, amiodarone.